Introducing MCO-010 and Its Impact
Nanoscope Therapeutics Inc. recently shared exciting long-term safety findings from their EXTEND study, which evaluated the outcomes of MCO-010, an optogenetic therapy aimed at treating advanced retinitis pigmentosa (RP). This therapy, leveraging Nanoscope's innovative Multi-Characteristic Opsin (MCO) platform, has shown promise for individuals suffering from severe vision impairment.
Long-Term Safety of MCO-010
The EXTEND study followed ten dedicated participants who had previously received a single infusion of MCO-010 as part of an early Phase 1/2a trial. Over an impressive five-year span, these participants reported sustained improvements in their quality of life. Notably, the study highlighted that MCO-010 remained safe and well tolerated, with no serious adverse effects or new safety concerns emerging during this time frame.
Key Findings from the EXTEND Study
Throughout the five-year follow-up, the safety profile of MCO-010 exhibited remarkable consistency. Participants experienced only manageable transient inflammation without any treatment terminations or significant side effects. According to Dr. Samarendra Mohanty, PhD, the President and Chief Scientific Officer of Nanoscope, the absence of serious safety signals and the strong retention of participants emphasizes MCO-010's potential as a long-lasting and non-invasive treatment option for patients facing severe vision loss from RP.
Durability of Effects
In the earlier trial, those who received higher doses of MCO-010 showed statistically significant enhancements in visual acuity within a year of treatment. Furthermore, participant reports indicated that vision-related quality of life remained stable or improved over the five years assessed, notably regarding distance vision tasks and activities requiring visual independence.
Presentation of Results
The compelling data resulting from the EXTEND study was presented at a prominent scientific gathering, aimed at sharing advancements in retinal research. The outcomes solidify Nanoscope's position at the forefront of research in vision restoration therapies.
About Nanoscope Therapeutics
Nanoscope Therapeutics strives to address the needs of millions affected by retinal degenerative disorders through its vision-restoring optogenetic therapies. Currently, the company is in the process of submitting a rolling Biologics License Application (BLA) for MCO-010 aimed at treating severe vision loss due to retinitis pigmentosa. If granted approval, MCO-010 could become a standard treatment option for patients grappling with this debilitating condition. Excitingly, Nanoscope has also begun to explore the efficacy of MCO-010 for other conditions, such as Stargardt disease (SD), and is anticipating the start of a Phase 2 program for geographical atrophy (GA) soon.
Contact Details
For further inquiries, please reach out to Nanoscope Therapeutics at (817) 857-1186 or via email.
Frequently Asked Questions
What is MCO-010?
MCO-010 is an optogenetic therapy developed by Nanoscope Therapeutics aimed at restoring vision in patients with serious eye conditions.
What were the key findings from the EXTEND study?
The EXTEND study confirmed that MCO-010 is safe and well tolerated over five years, with no serious adverse effects reported.
Who participated in the EXTEND study?
The study involved ten participants with advanced retinitis pigmentosa who received MCO-010 in a previous trial.
What are the implications of the study findings?
The study results indicate that MCO-010 could serve as a durable, non-invasive therapy for individuals experiencing severe vision loss due to RP.
What is Nanoscope’s future direction?
Nanoscope is advancing toward FDA approval of MCO-010 and expanding research on treatments for other retinal diseases.
